Tissue base test that screens 52 oncogenes/tumour suppressor genes for hotspot & RNA fusions with current treatment protocol of multiple cancers.
OncoFocus is multi-biomarker assay that enables the detection of hotpots, SNVs, indels, CNVs, and gene fusions across 52 cancer-relevant genes from DNA and RNA.
Categorized by somatic alteration type 52 genes
Hotspot Genes
- AKT1
- ALK
- AR
- BRAF
- CDK4
- CTNNB1
- DDR2
- EGFR
- ERBB2
- ERBB3
- ERBB4
- ESR1
- FGFR2
- FGFR3
- GNAll
- GNAQ
- HRAS
- IDH1
- IDH2
- JAK1
- JAK2
- JAK3
- KIT
- KRAS
- MAP2K1
- MAP2K2
- MET
- MTOR
- NRAS
- PDGFRA
- PIK3CA
- RAF1
- RET
- ROS1
- SMO
Copy Number Variants
- ALK
- AR
- BRAF
- CCND1
- CDK4
- CDK6
- EGFR
- ERBB2
- FGFR1
- FGFR2
- FGFR3
- FGFR4
- KIT
- RAS
- MET
- MYC
- MYCN
- PDGFRA
- PIK3CA
Fusion Drivers
- ABL1
- AKT3
- ALK
- AXL
- BRAF
- EGFR
- ERBB2
- ERG
- E71/1
- ETV4
- EN5
- FGFR1
- FGFR2
- FGFR3
- MET
- NTRK1
- NTRK2
- NTRK3
- PDGFRA
- PPARG
- RAF1
- RET
- ROS1
OncoFocus enables to
- Simultaneous detection of hundreds of variants across 52 genes relevant to solid tumors.
- Targets relevant hotspots, SNVs, indels, CNVs, and gene fusions from DNA or RNA in a single test.
- Enables detection of NTRK1, NTRK2, and NTRK3 gene fusions.
- Includes solid tumor genes targeted by on-market oncology drugs and published evidence
- Results from even small samples, such as fine-needle aspirates or as few as 2–3 FFPE slides
